92,234 Shares in QuidelOrtho Corporation $QDEL Acquired by Deutsche Bank AG

Deutsche Bank AG acquired a new stake in QuidelOrtho Corporation (NASDAQ:QDEL) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 92,234 shares of the company’s stock, valued at approximately $1,616,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Invesco Ltd. grew its stake in shares of QuidelOrtho by 87.0% during the third quarter. Invesco Ltd. now owns 2,906,763 shares of the company’s stock worth $85,604,000 after purchasing an additional 1,352,503 shares during the period. Rice Hall James & Associates LLC bought a new stake in shares of QuidelOrtho in the 2nd quarter valued at about $18,628,000. Newtyn Management LLC increased its stake in shares of QuidelOrtho by 58.3% in the 3rd quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock valued at $79,515,000 after acquiring an additional 994,332 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of QuidelOrtho by 101.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,755,401 shares of the company’s stock valued at $50,134,000 after acquiring an additional 883,077 shares during the period. Finally, T. Rowe Price Investment Management Inc. boosted its stake in QuidelOrtho by 7.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock worth $337,925,000 after acquiring an additional 819,908 shares during the last quarter. 99.00% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on QDEL. Zacks Research lowered shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 12th. JPMorgan Chase & Co. lifted their target price on QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a report on Wednesday, July 1st. Citigroup boosted their target price on QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. UBS Group reaffirmed a “neutral” rating and set a $12.00 price target on shares of QuidelOrtho in a research report on Thursday, May 7th. Finally, Wall Street Zen upgraded QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. Three analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, QuidelOrtho currently has a consensus rating of “Reduce” and a consensus target price of $13.62.

QuidelOrtho Trading Down 3.8%

NASDAQ QDEL opened at $14.74 on Friday. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -0.96 and a beta of 0.68. QuidelOrtho Corporation has a 52 week low of $9.92 and a 52 week high of $35.58. The stock’s 50 day moving average price is $15.93 and its two-hundred day moving average price is $16.04. The company has a debt-to-equity ratio of 1.43, a quick ratio of 0.76 and a current ratio of 1.39.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.18. The company had revenue of $630.90 million for the quarter, compared to the consensus estimate of $618.72 million. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The firm’s revenue was up 2.8% compared to the same quarter last year. During the same period last year, the company earned $0.12 earnings per share. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. As a group, analysts anticipate that QuidelOrtho Corporation will post 0.75 earnings per share for the current fiscal year.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.